Effect of RAD18-siRNA on proliferation and chemotherapy sensitivity of human esophageal squamous cell carcinoma ECA-109 cells / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
; (6): 364-370, 2016.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-239577
Biblioteca responsável:
WPRO
ABSTRACT
To investigate the effect of RAD18-siRNA on cell proliferation and chemotherapy sensitivity of esophageal squamous cell carcinoma (ESCC) ECA-109 cells.RAD18-siRNA was transfected into human ECA-109 cells by Lipofectamine 3000. Quantitative PCR and Western blot were performed to detect RAD18 and CyclinD1 expression; CCK-8 assay was used to determine cell proliferation and chemotherapy drug sensitivity; flow cytometry was used to determine cell cycle. Correlation between RAD18 and CyclinD1 mRNA expression was analyzed by Pearson's correlation.Compared with non-transfected cells, the expression of RAD18 in RAD18-siRNA group was significantly decreased (<0.05). The cell proliferation was inhibited (<0.05) and the cell number of G1 phase was increased, G2/M phase cells decreased (<0.05) in RAD18-siRNA group. After treatment with different concentrations of cisplatin or 5-FU, the survival rate of the two cell groups was reduced (all<0.05), and the IC50 of RAD18-siRNA group was significantly lower than that of non-transfected group (<0.05). The mRNA expression of RAD18 was positively correlated with CyclinD1 expression in ESCC tissues(=0.478,<0.01).Down-regulated expression of RAD18 can decrease the cell proliferation and increase chemo-sensitivity of ESCC cells, and CyclinD1 may participate in the process.
Texto completo:
Disponível
Contexto em Saúde:
ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis
Problema de saúde:
Doenças do Sistema Digestório
/
Neoplasia Esofágica
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Farmacologia
/
Neoplasias Esofágicas
/
Ensaios de Seleção de Medicamentos Antitumorais
/
Carcinoma de Células Escamosas
/
Transfecção
/
Regulação para Baixo
/
Ciclo Celular
/
Adjuvantes Farmacêuticos
/
Fase G1
/
Fase G2
Limite:
Humanos
Idioma:
Chinês
Revista:
Journal of Zhejiang University. Medical sciences
Ano de publicação:
2016
Tipo de documento:
Artigo